Principia biopharma inc. (PRNB)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Dec'17
Assets
Current assets:
Cash and cash equivalents

59,427

39,537

29,411

41,073

14,670

34,489

149,053

41,054

Short-term marketable securities

252,042

276,043

121,293

128,492

148,949

142,436

39,239

0

Restricted cash

-

-

0

0

0

82

82

100

Prepaid expenses and other current assets

4,627

4,165

1,658

2,157

3,294

3,765

2,506

1,778

Total current assets

316,096

319,745

152,362

171,722

166,913

180,772

190,880

42,932

Property and equipment, net

9,363

9,687

10,165

10,598

10,671

1,666

552

209

Operating lease right-of-use asset

6,624

0

-

-

-

-

-

-

Restricted cash

567

567

567

567

567

567

567

82

Long-term marketable securities

29,645

52,257

10,513

8,972

0

3,712

-

0

Other long-term assets

480

480

480

480

480

8,804

8,574

280

Total assets

362,775

382,736

174,087

192,339

178,631

195,521

200,573

43,503

Liabilities and stockholders' equity
Current liabilities:
Accounts payable

1,623

1,850

2,323

4,052

4,182

4,439

4,749

3,405

Deferred rent, current portion

0

1,181

1,156

1,132

1,105

344

-

-

Operating lease liability, current portion

1,829

0

-

-

-

-

-

-

Deferred revenue

-

-

0

0

0

5,616

20,637

44,134

Accrued research and development liabilities

10,365

5,791

5,047

4,823

2,680

1,520

-

1,177

Accrued other liabilities

956

602

620

591

958

649

-

253

Accrued liabilities

-

-

-

-

-

-

4,205

-

Accrued compensation

3,248

6,715

4,350

2,850

2,224

4,312

1,953

2,262

Total current liabilities

18,021

16,139

13,496

13,448

11,149

16,880

31,544

51,231

Deferred revenue, less current portion

-

-

-

-

-

-

1,116

5,619

Long-term deferred rent

0

7,619

7,916

8,213

8,492

8,781

8,827

8

Long-term operating lease liability

13,306

0

-

-

-

-

-

-

Convertible preferred stock warrant liability

-

-

-

-

-

-

0

1,576

Total liabilities

-

-

-

-

-

-

41,487

58,434

Commitments and contingencies (Note 7)

-

-

-

-

-

-

0

-

Convertible preferred stock, $0.0001 par value, 20,000,000 and 113,680,282 shares authorized at December 31, 2018 and 2017, respectively; 0 and 12,285,434 shares issued and outstanding at December 31, 2018 and 2017, respectively (aggregate liquidation preference of $0 and $129,445 at December 31, 2018 and 2017)

-

-

-

-

-

-

0

128,531

Stockholders' equity
Common stock, $0.0001 par value, 500,000,000 shares authorized at March 31, 2020 and December 31, 2019; 33,026,825 and 32,950,836 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

3

3

2

2

2

2

2

1

Additional paid-in capital

549,622

544,709

313,414

309,088

304,605

302,393

300,968

7,201

Accumulated other comprehensive income

65

9

78

111

21

-128

-100

-90

Accumulated deficit

-218,242

-185,743

-160,819

-138,523

-145,638

-132,407

-141,784

-150,574

Total stockholders' equity

331,448

358,978

152,675

170,678

158,990

169,860

159,086

-143,462

Total liabilities and stockholders’ equity

362,775

382,736

174,087

192,339

178,631

195,521

200,573

43,503